517 related articles for article (PubMed ID: 32447795)
1. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
Pena E; Ahmed S
Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
[No Abstract] [Full Text] [Related]
2. Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2).
Leppla IE; Gross MS
J Addict Med; 2020; 14(4):e1-e3. PubMed ID: 32412931
[TBL] [Abstract][Full Text] [Related]
3. Challenges of methadone maintenance treatment during the COVID-19 epidemic in China: Policy and service recommendations.
Jiang H; Su H; Zhang C; Liu X; Li R; Zhong N; Zhao M
Eur Neuropsychopharmacol; 2020 Jun; 35():136-137. PubMed ID: 32307223
[No Abstract] [Full Text] [Related]
4. Opioid Use Disorder and COVID-19: Crashing of the Crises.
Khatri UG; Perrone J
J Addict Med; 2020; 14(4):e6-e7. PubMed ID: 32404651
[TBL] [Abstract][Full Text] [Related]
5. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G; Bruneau J; Cox N; Gordon AJ
Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
[TBL] [Abstract][Full Text] [Related]
6. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
Wilson CG; Ramage M; Fagan EB
J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
[No Abstract] [Full Text] [Related]
7. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
[TBL] [Abstract][Full Text] [Related]
8. Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia.
Roberts J; White B; Attalla D; Ward S; Dunlop AJ
Addiction; 2021 Feb; 116(2):426-427. PubMed ID: 32888226
[No Abstract] [Full Text] [Related]
9. Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?
Krawczyk N; Fingerhood MI; Agus D
J Subst Abuse Treat; 2020 Oct; 117():108074. PubMed ID: 32680610
[No Abstract] [Full Text] [Related]
10. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
Soyka M; Hillemacher T
Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
[No Abstract] [Full Text] [Related]
11. Innovations in efforts to expand treatment for opioid use disorder.
Sigmon SC
Prev Med; 2019 Nov; 128():105818. PubMed ID: 31445112
[TBL] [Abstract][Full Text] [Related]
12. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
13. Overdue for an Overhaul: How Opioid Treatment Programs Can Learn From COVID-19.
Greenblatt AD; Magidson JF; Belcher AM; Gandhi D; Weintraub E
Mayo Clin Proc; 2020 Oct; 95(10):2076-2078. PubMed ID: 33012340
[No Abstract] [Full Text] [Related]
14. Innovation During COVID-19: Improving Addiction Treatment Access.
Samuels EA; Clark SA; Wunsch C; Jordison Keeler LA; Reddy N; Vanjani R; Wightman RS
J Addict Med; 2020; 14(4):e8-e9. PubMed ID: 32404652
[TBL] [Abstract][Full Text] [Related]
15. Medication-Based Treatment to Address Opioid Use Disorder.
Leshner AI; Dzau VJ
JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
[No Abstract] [Full Text] [Related]
16. A New Way Forward in the Emergency Department.
Schwarz ES; Laes JR; Wiegand TJ
J Med Toxicol; 2019 Oct; 15(4):220-222. PubMed ID: 31278586
[No Abstract] [Full Text] [Related]
17. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
Martell JP; Konakanchi JS; Sethi R
J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
[TBL] [Abstract][Full Text] [Related]
18. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
Chou R; Ballantyne J; Lembke A
Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
[No Abstract] [Full Text] [Related]
19. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Bishop B; Gilmour J; Deering D
Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
[TBL] [Abstract][Full Text] [Related]
20. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
